https://ymaho.com/ema-safety-study-of-vocabria-hepatotoxicity-and-pregnancy
EMA requires long-term monitoring of Vocabria (cabotegravir + rilpivirine) due to risks of hepatotoxicity, pregnancy outcomes, and resistance. Learn about the findings and implications.